"Precision Medicine in Oncology " Virtual Event
Source: RNS
Diaceutics and Labroots Announce "Precision Medicine in Oncology " Virtual Event:
A Cutting-Edge Exploration of Cancer Diagnostics & Treatment
Belfast and London, 13 June 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce its upcoming virtual event to be hosted in collaboration with Labroots - "Precision medicine in oncology," on 19 June, 2024.
This groundbreaking event will take attendees to the forefront of cancer testing & treatment through a series of eight live webinars, culminating in a full day of immersive, true-to-life virtual experiences. The virtual sessions will cover topics that are revolutionising cancer analysis & diagnostics, including immunotherapy; liquid biopsy; pre-analytical phase; NGS; Cytology and CE marked Invitro-Diagnostic Regulations.
Event Speakers will include:
|
· |
Prof. Dr. Klaus Pantel, Director of the Institute of Tumor Biology at the University Medical Center Hamburg-Eppendorf, Germany: Presenting "Implementation of Liquid Biopsy in Precision Oncology," Prof. Pantel, a pioneer in cancer cell research, will provide a comprehensive introduction to and review of the evolution of precision medicine, focusing on the implementation of liquid biopsy in precision oncology. |
|
· |
Dr. Bob Holt, Senior Precision Medicine Strategy Advisor at Diaceutics: Presenting "MRD in Solid Tumor and Hematological Indications: Today and Tomorrow," Dr. Holt will analyse the clinical utility and technology behind Minimal Residual Disease (MRD). This session will be followed by Prof. Maria Teresa Voso, Prof. of Hematology at Tor Vergata University, who will discuss the pros and cons of MRD in AML and engage in a discussion with Dr. Holt and all attendees. |
|
· |
Prof. Paul Hoffman, Professor of Pathology at the University Côte d'Azur, Nice, France: Presenting on "New challenges in early-stage cancer". This presentation will explore early detection and management of early-stage cancers. |
|
· |
Dr. Clare Turnbull, PhD FRCP FRCPath FFPH, Professor of Translational Cancer Genetics in the Division of Genetics & Epidemiology at the Institute of Cancer Research and NHS Honorary Consultant in Clinical Cancer Genetics, London and Dr Nicola Normanno, MD, Director of Translational Research, National Cancer Institute, Pascale Foundation, Italy: Presenting "The Role of Comprehensive Genomic Profiling in Precision Oncology," this session promises insights into the implications of large NGS panels, co-mutations, and the introduction of patients harboring germline variants. |
|
· |
Prof. Sophie Prévot, Pathologist at the Bicêtre Hospital, Paris: Presenting "Integrating AI in Pathology: Advancing Diagnoses & Workflow Efficiency," this presentation will explore how AI tools can support doctors in making accurate diagnoses and enhancing workflow efficiency. |
Ryan Keeling, CEO of Diaceutics, commented, "Our commitment is to transform the landscape of cancer treatment through precision medicine. This event provides an unparalleled platform for experts to share innovative practices and insights that will shape the future of oncology diagnostics. We are pleased to host this gathering of thought leaders and advance our mission of ensuring every patient receives the right treatment at the right time."
The event is tailored for laboratory professionals, pathologists, and anyone involved in oncology diagnostics and treatment. In addition to the expert presentations, attendees can participate in interactive sessions, visit the poster hall, and engage in real-time Q&A sessions with expert speakers.
For further information about the event and to register for free, click here.
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.
About Labroots
Labroots is the leading scientific social networking website, and primary source for scientific trending news and premier educational virtual events and webinars and more. Contributing to the advancement of science through content sharing capabilities, Labroots is a powerful advocate in amplifying global networks and communities. Founded in 2008, Labroots emphasises digital innovation in scientific collaboration and learning. Offering more than articles and webcasts that go beyond the mundane and explore the latest discoveries in the world of science, Labroots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars and virtual events.
Enquiries:
|
Diaceutics PLC |
|
|
Ryan Keeling, Chief Executive Officer Nick Roberts, Chief Financial Officer
|
Tel: +44 (0)28 9040 6500 investorrelations@diaceutics.com
|
|
Stifel Nicolaus Europe Limited (Nomad & Broker) |
Tel: +44 (0)20 7710 7600 |
|
Ben Maddison |
|
|
Nick Harland |
|
|
Kate Hanshaw |
|
|
|
|
|
Alma Strategic Communications |
Tel: +44(0)20 3405 0205 |
|
Caroline Forde Kinvara Verdon Kieran Breheny |
diaceutics@almastrategic.com |
|
|
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
